Stereotactic Radiation and Nivolumab in the Management of Metastatic Breast Cancer Brain Metastases
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Nivolumab
Related studies linked through entity extraction aliases.
Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Nivolumab and Pomalidomide in Treating Patients With Relapsed or Refractory Central Nervous System Diffuse Large B Cell Lymphoma or Primary Vitreoretinal Diffuse Large B Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study of BMS-986205 Alone and in Combination With Nivolumab in Chinese Patients With Advanced Malignant Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.
- Status
- UNKNOWN
- Phase
- PHASE1
Dendritic Cell (DC)/Myeloma Fusions in Combination With Nivolumab in Patients With Relapsed Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE2
Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Nivolumab and Ibrutinib in Treating Patients With Relapsed or Refractory Central Nervous System Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
An Investigational Immuno-therapy Study of Nivolumab Given After Surgery in Non-Small Cell Lung Cancer (NSCLC) Participants With Minimal Residual Disease
- Status
- WITHDRAWN
- Phase
- PHASE2
VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2